Zymeworks Inc（ZYME）股票分析ZYMEZymeworks Inc

Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zymeworks Inc (ZYME) is a good buy right now due to its recent FDA approval for Ziihera, which has significantly improved its financial outlook with a potential milestone payment of $250 million. The current price is $28.27, and analysts see an upside potential of 87% based on the new price target of $55. However, the company has a high forward P/E ratio of 94.34, indicating that investors are expecting substantial future growth, which is a risk if the company does not meet these expectations.

4 analysts cover ZYME: 3 rate it Buy, 0 Hold and 1 Sell. The average price target is 35.55.